Fig. 5
From: A novel small compound TOIDC suppresses lipogenesis via SREBP1-dependent signaling to curb MAFLD
Administration of TOIDC in DIO mice curbs MAFLD and obesity (n = 5 in each group). A Ultrasound photo of diet-induced obese (DIO) mice before treatment. B The serum ALT activity of DIO mice administered with TOIDC or Vehicle. C The serum AST activity of DIO mice administered with TOIDC or Vehicle. D Representative of the livers of the vehicle or TOIDC treatment DIO mice. E Liver weight of the vehicle or TOIDC treatment DIO mice. F Body weight curve of DIO during TOIDC treatment mice. G Representative of DIO and fat pad photos of vehicle or TOIDC treatment DIO mice. H Triglyceride content in liver of vehicle or TOIDC treatment DIO mice. I Nile staining of liver tissue of vehicle or TOIDC treatment DIO mice. Scale bar, 100 µm. J H&E staining of liver tissue of vehicle or TOIDC treatment DIO mice. Scale bar, 100 µm. K The abundance of lipogenesis related mRNAs in the liver of DIO mice. L The abundance of lipogenesis related protein in the liver of DIO mice. Data are presented as mean ± SEM of three independent biological replicates; *P < 0.05; **P < 0.01; ns no significance